Zhengye Biotechnology Holding (ZYBT) Receivables (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Receivables for 3 consecutive years, with $5.3 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables fell 51.11% year-over-year to $5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.3 million (down 51.11% YoY) and the FY2025 annual result came in at $8.4 million, down 22.02% from the prior year.
• Receivables slipped to $5.3 million in Q4 2025 per ZYBT's latest filing, from $6.4 million in the prior quarter.
• Over the last five years, Receivables for ZYBT reached as high as $13.1 million in Q4 2023 and fell as low as $5.3 million in Q4 2025.
• A 3-year average of $8.9 million and a median of $8.6 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables slipped 17.78% — and 2025, when it plunged 51.11%.
• Year by year, Receivables stood at $13.1 million in 2023, then fell by 17.78% to $10.7 million in 2024, then tumbled by 51.11% to $5.3 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $5.3 million, $6.4 million, and $10.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.